<DOC>
	<DOCNO>NCT00003091</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . Interleukin-2 may stimulate person 's white blood cell kill kidney cancer melanoma cell . PURPOSE : Phase II trial study effectiveness high-dose interferon alfa interleukin-2 treating patient metastatic kidney cancer melanoma .</brief_summary>
	<brief_title>High-Dose Interferon Alfa Interleukin-2 Treating Patients With Metastatic Kidney Cancer Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety , efficacy , antitumor activity high dose interferon alfa-2b interleukin-2 patient metastatic renal cell carcinoma melanoma . II . Determine toxic effect interferon alfa-2b interleukin-2 patient . OUTLINE : This open label study . Patients receive subcutaneous interferon alfa-2b day 1-4 . Patients hospitalize receive bolus infusion interleukin-2 ( IL-2 ) follow continuous infusion day 5-7 . Patients observe least 12 hour follow IL-2 treatment . Treatment repeat every 4 week disease progression maximum six cycle . Patients follow every 2 month one year , survival . PROJECTED ACCRUAL : If least 1 response see first 14 patient group , maximum 40 patient per group accrue .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic renal cell carcinoma melanoma Measurable evaluable disease No active brain metastasis Previously treat CNS metastasis respond therapy eligible , CNS site evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance Status : ECOG 02 Life Expectancy : Not specify Hematopoietic : Hematocrit least 25 WBC least 3,000/mm3 Platelet count least 100,000/mm3 PT PTT within normal limit Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine le 2.0 mg/dL Cardiovascular : No myocardial infarction within 6 month No medication congestive heart failure cardiac arrhythmia No hypertension ( unless blood pressure stable medication ) Pulmonary : Must reasonable respiratory reserve require supplemental oxygen No dyspnea rest Oxygen saturation must great 90 % patient risk respiratory symptom Other : Not HIV positive Not positive hepatitis B antigen No chronic underlie immunodeficiency No concurrent active infection require antibiotic therapy Not pregnant nursing No concurrent serious illness No family history malignant hyperthermia No hypersensitivity interferon alfa2b interleukin2 PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interleukin2 interferon alfa2b combination therapy Chemotherapy : No prior systemic chemotherapy within 4 week study recover Endocrine therapy : No concurrent corticosteroid therapy Radiotherapy : No prior radiotherapy within 4 week interleukin2 therapy No prior stereotactic radiosurgery gamma knife therapy within 1 week interleukin2 therapy Surgery : No prior organ allograft transplantation Must recover prior surgery Other : No concurrent cyclosporin therapy No concurrent treatment anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>